Publications | PubMed=6954533; DOI=10.1073/pnas.79.7.2194; PMCID=PMC346157 Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A., Aaronson S.A., Wong-Staal F. Differential expression of the amv gene in human hematopoietic cells. Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982) PubMed=6372095; DOI=10.1126/science.6372095 Rogan A.M., Hamilton T.C., Young R.C., Klecker R.W. Jr., Ozols R.F. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224:994-996(1984) PubMed=3986765 Louie K.G., Behrens B.C., Kinsella T.J., Hamilton T.C., Grotzinger K.R., McKoy W.M., Winker M.A., Ozols R.F. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res. 45:2110-2115(1985) PubMed=2429947; DOI=10.20772/cancersci1985.77.9_941 Tsuruo T., Hamilton T.C., Louie K.G., Behrens B.C., Young R.C., Ozols R.F. Collateral susceptibility of adriamycin-, melphalan- and cisplatin-resistant human ovarian tumor cells to bleomycin. Jpn. J. Cancer Res. 77:941-945(1986) PubMed=3539322 Behrens B.C., Hamilton T.C., Masuda H., Grotzinger K.R., Whang-Peng J., Louie K.G., Knutsen T., McKoy W.M., Young R.C., Ozols R.F. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 47:414-418(1987) PubMed=3335022 Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48:589-601(1988) PubMed=2751261 Mazzoni A., Trave F., Canti G., Franco P. Effect of the tiapamil analog RO11-2933 on cellular sensitivity to antitumor drugs in sensitive and multidrug resistant human ovarian cancer cells. Anticancer Res. 9:367-371(1989) PubMed=1999494; DOI=10.1172/JCI115080; PMCID=PMC329864 Parker R.J., Eastman A., Bostick-Bruton F., Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin. Invest. 87:772-777(1991) PubMed=1348364; DOI=10.1073/pnas.89.7.3070; PMCID=PMC48805 Godwin A.K., Meister A., O'Dwyer P.J., Huang C.-S., Hamilton T.C., Anderson M.E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. U.S.A. 89:3070-3074(1992) PubMed=8012063 Cimoli G., Valenti M., Parodi S., Mazzoni A., De Sessa F., Conte P., Russo P. Reversal of 'atypical'-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3. Oncol. Res. 5:311-323(1993) PubMed=7927910; DOI=10.1002/ijc.2910590118 Huxham I.M., Barlow A.L., Lewis A.D., Plumb J., Mairs R.J., Gaze M.N., Workman P. Differential intracellular processing of the anthracycline drug ME2303 in doxorubicin-sensitive (A2780) and -resistant (A2780AD) human ovarian cancer cells as studied with confocal laser scanning microscopy and image analysis. Int. J. Cancer 59:94-102(1994) PubMed=8557231; DOI=10.1006/gyno.1996.0014 Skilling J.S., Squatrito R.C., Connor J.P., Niemann T., Buller R.E. p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines. Gynecol. Oncol. 60:72-80(1996) PubMed=9041185 Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., Hamilton T.C. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res. 57:850-856(1997) PubMed=11103784 Hough C.D., Sherman-Baust C.A., Pizer E.S., Montz F.J., Im D.D., Rosenshein N.B., Cho K.R., Riggins G.J., Morin P.J. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 60:6281-6287(2000) PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459 Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001) PubMed=12080474; DOI=10.1038/sj.onc.1205542 Manzano R.G., Montuenga L.M., Dayton M.A., Dent P., Kinoshita I., Vicent S., Gardner G.J., Nguyen P., Choi Y.-H., Trepel J.B., Auersperg N., Birrer M.J. CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential. Oncogene 21:4435-4447(2002) PubMed=15677628; DOI=10.1093/carcin/bgi032 Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C. Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer. Carcinogenesis 26:923-930(2005) PubMed=18273836; DOI=10.1002/gcc.20547 Prasad M., Bernardini M., Tsalenko A., Marrano P., Paderova J., Lee C.-H., Ben-Dor A., Barrett M.T., Squire J.A. High definition cytogenetics and oligonucleotide aCGH analyses of cisplatin-resistant ovarian cancer cells. Genes Chromosomes Cancer 47:427-436(2008) PubMed=19714814; DOI=10.1021/pr800856b Cicchillitti L., Di Michele M., Urbani A., Ferlini C., Donati M.B., Scambia G., Rotilio D. Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57. J. Proteome Res. 8:1902-1912(2009) PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113 Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R. Signatures of mutation and selection in the cancer genome. Nature 463:893-898(2010) PubMed=20204287; DOI=10.3892/or_00000728; PMCID=PMC2909445 Langland G.T., Yannone S.M., Langland R.A., Nakao A., Guan Y.-H., Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q. Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities. Oncol. Rep. 23:1021-1026(2010) PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662 Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 70:2158-2164(2010) PubMed=22328975; DOI=10.1158/2159-8290.CD-11-0170; PMCID=PMC3274821 Hanrahan A.J., Schultz N., Westfal M.L., Sakr R.A., Giri D.D., Scarperi S., Janakiraman M., Olvera N., Stevens E.V., She Q.-B., Aghajanian C., King T.A., de Stanchina E., Spriggs D.R., Heguy A., Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B. Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov. 2:56-67(2012) PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027 Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607(2012) PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224; PMCID=PMC5057396 Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.-Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J. Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov. 2:172-189(2012) PubMed=22705003; DOI=10.1016/j.humpath.2012.03.011 Rahman M., Nakayama K., Rahman M.T., Nakayama N., Ishikawa M., Katagiri A., Iida K., Nakayama S., Otsuki Y., Shih I.-M., Miyazaki K. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. Hum. Pathol. 43:2197-2206(2012) PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017; PMCID=PMC3432677 Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P. DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol. Oncol. 127:241-248(2012) PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007; PMCID=PMC4106023 Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G., Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J., Mills G.B., Hennessy B.T. BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Mol. Oncol. 7:567-579(2013) PubMed=23839242; DOI=10.1038/ncomms3126; PMCID=PMC3715866 Domcke S., Sinha R., Levine D.A., Sander C., Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4:2126.1-2126.10(2013) PubMed=24023729; DOI=10.1371/journal.pone.0072162; PMCID=PMC3762837 Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M., Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R., Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G. Type-specific cell line models for type-specific ovarian cancer research. PLoS ONE 8:E72162-E72162(2013) PubMed=25230021; DOI=10.1371/journal.pone.0103988; PMCID=PMC4167545 Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M., Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J., Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J., Helleman J. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS ONE 9:E103988-E103988(2014) PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652 Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci. Data 1:140035-140035(2014) PubMed=25485619; DOI=10.1038/nbt.3080 Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M. A comprehensive transcriptional portrait of human cancer cell lines. Nat. Biotechnol. 33:306-312(2015) PubMed=25846456; DOI=10.3892/ijo.2015.2951 Takenaka M., Saito M., Iwakawa R., Yanaihara N., Saito M., Kato M., Ichikawa H., Shibata T., Yokota J., Okamoto A., Kohno T. Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing. Int. J. Oncol. 46:2389-2398(2015) PubMed=25877200; DOI=10.1038/nature14397 Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M. A resource for cell line authentication, annotation and quality control. Nature 520:307-311(2015) PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878 Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C. TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression. Genome Med. 7:118.1-118.7(2015) PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008 Masuishi Y., Kimura Y., Arakawa N., Hirano H. Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment. J. Proteomics 139:77-83(2016) PubMed=27141528; DOI=10.1016/j.dib.2016.04.001; PMCID=PMC4838930 Masuishi Y., Kimura Y., Arakawa N., Hirano H. Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines. Data Brief 7:1302-1305(2016) PubMed=27235858; DOI=10.1016/j.ygyno.2016.05.028; PMCID=PMC4961516 Hernandez L., Kim M.K., Lyle L.T., Bunch K.P., House C.D., Ning F., Noonan A.M., Annunziata C.M. Characterization of ovarian cancer cell lines as in vivo models for preclinical studies. Gynecol. Oncol. 142:332-340(2016) PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469 Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J. A landscape of pharmacogenomic interactions in cancer. Cell 166:740-754(2016) PubMed=27561551; DOI=10.1038/ncomms12645; PMCID=PMC5007461 Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.-Y., Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M. Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nat. Commun. 7:12645.1-12645.14(2016) PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076 Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H. Characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell 31:225-239(2017) PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028 Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J., Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A., Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J., Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R. Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer. Cell Rep. 18:2343-2358(2017) PubMed=28546799; DOI=10.1186/s12014-017-9155-z; PMCID=PMC5442857 Zhao R., Qin W.-J., Qin R.-H., Han J., Li C., Wang Y.-S., Xu C.-J. Lectin array and glycogene expression analyses of ovarian cancer cell line A2780 and its cisplatin-resistant derivate cell line A2780-cp. Clin. Proteomics 14:20.1-20.10(2017) PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096; PMCID=PMC6481945 Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M., Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R., Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J., Velculescu V.E., Scharpf R.B. Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines. Cell Rep. 25:2617-2633(2018) PubMed=30894224; DOI=10.1186/s40659-019-0220-0; PMCID=PMC6427839 Viscarra T., Buchegger K., Jofre I.A., Riquelme I., Zanella L., Abanto Marin M., Parker A.C., Piccolo S.R., Roa J.C., Ili C.G., Brebi P. Functional and transcriptomic characterization of carboplatin-resistant A2780 ovarian cancer cell line. Biol. Res. 52:13.1-13.13(2019) PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675 Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019) PubMed=30971826; DOI=10.1038/s41586-019-1103-9 Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature 568:511-516(2019) PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019) PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254 Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P. Quantitative proteomics of the Cancer Cell Line Encyclopedia. Cell 180:387-402.e16(2020) PubMed=33287223; DOI=10.3390/ijms21239218; PMCID=PMC7730278 Szenajch J., Szabelska-Beresewicz A., Swiercz A., Zyprych-Walczak J., Siatkowski I., Goralski M., Synowiec A., Handschuh L. Transcriptome remodeling in gradual development of inverse resistance between paclitaxel and cisplatin in ovarian cancer cells. Int. J. Mol. Sci. 21:9218.1-9218.30(2020) PubMed=34071702; DOI=10.3390/ijms22115814; PMCID=PMC8198185 Golan Berman H., Chauhan P., Shalev S., Hassanain H., Parnas A., Adar S. Genomic characterization of cisplatin response uncovers priming of cisplatin-induced genes in a resistant cell line. Int. J. Mol. Sci. 22:5814.1-5814.14(2021) PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775 Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R. Pan-cancer proteomic map of 949 human cell lines. Cancer Cell 40:835-849.e8(2022) |